Celldex Therapeutics to Present at Upcoming Investor Conferences

Celldex Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates

Celldex: Q3 Earnings Snapshot

Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Celldex selloff creates buying opportunity, says Guggenheim

Celldex Therapeutics (NASDAQ:CLDX) pulls back 6.1% this week, but still delivers shareholders fantastic 57% CAGR over 5 years

Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria

Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024

Celldex Therapeutics (CLDX): A Top Small-Cap Growth Stock with Promising Clinical Results

Celldex Therapeutics, Inc. (CLDX): Hedge Funds’ Hidden Gem in Small-Cap Stocks

CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study